TSE:TR Trillium Therapeutics (TR) Stock Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume49,075 shsAverage Volume99,071 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Trillium Therapeutics alerts: Email Address Ad InvestorPlace44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.The information in this video is crucially valuable. About Trillium Therapeutics Stock (TSE:TR)Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17.Read More Ad InvestorPlace44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. But now a looming disaster is threatening America. And it's unlike anything we've ever experienced before.The information in this video is crucially valuable. TR Stock News HeadlinesMay 28, 2024 | msn.comKabete National Polytechnic Ranked Best TTI in New Timely Kenya SurveyMay 28, 2024 | theglobeandmail.comPension plans still AWOL as Canadian life-sciences venture capital firms re-up for latest fundsSeptember 16, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 7, 2024 | finance.yahoo.comNimbus Therapeutics Appoints Anita Scheuber, M.D., Ph.D., as Senior Vice President, Therapeutic Area Head, OncologyMay 6, 2024 | finance.yahoo.comRatio Therapeutics Announces the Appointment of Marc Becker as Chief Financial Officer and Chief Operating OfficerApril 15, 2024 | finance.yahoo.comSezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura BioApril 2, 2024 | finance.yahoo.comUpstream Bio Announces Appointment of Rand Sutherland as CEO and Additions to Leadership TeamMarch 12, 2024 | finance.yahoo.comRatio Announces Expansion of Manufacturing Agreement with PharmaLogic for FAP-Targeted RadiopharmaceuticalsSeptember 16, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.January 17, 2024 | bizjournals.comRatio Therapeutics raises $50M for tumor-targeting radiopharmaceuticalsJune 22, 2023 | finance.yahoo.comTvardi Therapeutics Announces First Patients Dosed in its Phase 2 Liver Cancer Trial Using TTI-101, a Novel STAT3 InhibitorJune 20, 2023 | benzinga.comPD-1 Non-Small Cell Lung Cancer Clinical Trials Pipeline Analysis: 20+ Companies are Working to Improve the Treatment Space | DelveInsightMay 9, 2023 | finance.yahoo.comRatio Therapeutics Announces Opening of New Research and Development FacilityApril 25, 2023 | finance.yahoo.comTrillium Engineering Announces Its Latest Innovation in Cameras Utilizing AI Technology - HD80-AIMMarch 10, 2023 | msn.comWho's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In PersonFebruary 6, 2023 | finanznachrichten.deViridian Therapeutics, Inc: Viridian Appoints Scott Myers as President and Chief Executive OfficerJanuary 28, 2023 | detroitnews.comTaylor Trillium building into Division 4 state power, behind coach Terrell GeorgeDecember 19, 2022 | benzinga.comLeiomyosarcoma Drug Pipeline Research Report 2022: Comprehensive Insights on 18+ Companies and 18+ Pipeline DrugsSee More Headlines Receive TR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeTSE SectorManufacturing Industry Sugar And Confectionery Products Sub-IndustryFood Products Current SymbolTSE:TR CUSIPN/A CIKN/A Webwww.trilliumtherapeutics.com Phone+1-416-5950627FaxN/AEmployees2,000Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesCalvin R. Stiller M.D.Independent Chairman of the BoardNiclas StiernholmPresident, Chief Executive Officer, DirectorJames T. ParsonsChief Financial OfficerMalik SlassiSenior Vice President - Discovery ResearchRobert UgerChief Scientific OfficerScott DuncanDirector of Intellectual PropertyPenka PetrovaChief Development OfficerEric L SieversChief Medical OfficerLuke M. Beshar CPA (Age 59)Independent Director Henry Friesen M.D. (Age 79)Independent Director More ExecutivesKey CompetitorsKinross GoldTSE:KDominion DiamondTSE:DDCKelt ExplorationTSE:KELHNZ GroupTSE:HNZTelson MiningCVE:TSNView All Competitors TR Stock Analysis - Frequently Asked Questions How do I buy shares of Trillium Therapeutics? Shares of TR stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Trillium Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trillium Therapeutics investors own include Cedar Fair (FUN), Trillium Therapeutics (TRIL), Ford Motor (F), Express Scripts (ESRX), Esperion Therapeutics (ESPR), ConocoPhillips (COP). This page (TSE:TR) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trillium Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Trillium Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.